Gut dysbiosis and systemic inflammation promote cardiomyocyte abnormalities in an experimental model of steatohepatitis

Table 2 Correlation of steatohepatitis, cardiovascular risk, and microbiota composition

Variable1		Severity and progression of liver injury				CVR factors and metabolism of lipids						Cardiomyocyte morphometry			Microbiota composition
		Quantification of collagen (picrosirius)	TIMP-1	MCP-1	IL-1β	miR-33a	miR-126	PAI-1	CRI-I	CRI-II	AC	% Normal CAR	Average area of CAR	% Atrophic CAR
Severity and progression of liver injury	NAFLD score	0.8792	0.7912	0.6732	0.347	0.6392	-0.7772	0.4443	0.8092	0.8202	0.8092	-0.5193	-0.6302	0.7212	0.6942
	Quantification of collagen (picrosirius)		0.6112	0.4563	0.7522	0.5713	-0.6832	0.415	0.8192	0.8212	0.8192	-0.205	-0.312	0.238	0.3782
	TIMP-1			0.8032	0.7262	0.7282	-0.8122	0.5353	0.6912	0.7472	0.6912	-0.6942	-0.405	0.6072	0.5392
	MCP-1				0.5673	0.4923	-0.6232	0.336	0.5493	0.5613	0.5493	-0.4903	-0.390	0.4983	0.2323
	IL-1β					0.8092	-0.6883	0.5443	0.6453	0.6882	0.6453	-0.4373	-0.393	0.382	0.2933
CVR factors and metabolism of lipids	miR-33a						-0.6552	0.363	0.5293	0.6033	0.5293	-0.7042	0.038	0.232	0.1603
	miR-126							-0.6342	-0.7122	-0.7302	-0.7122	0.4593	0.320	-0.364	0.3682
	PAI-1								0.4873	0.6712	0.4873	-0.317	0.389	-0.289	0.103
	CRI-I									0.8632	1.0002	-0.234	-0.4593	0.386	0.4692
	CRI-II										0.8632	-0.399	-0.4923	0.5513	0.5842
	AC											-0.236	-0.4573	0.389	0.4772
Cardiomyocyte morphometry	% Normal cardiomyocytes												0.105	-0.058
	% Average area of cardiomyocytes													-0.8182
	% Atrophic cardiomyocytes

¹Variables were evaluated by Spearman's r correlation coefficient: moderate (0.3 < r < 0.6), strong (0.6 < r < 0.9) or very strong (0.9 < r < 1.0).

²Correlation significant at the 0.01 level.

³Correlation significant at the 0.05 level.

AC: Atherogenic coefficient; CAR: Cardiomyocytes; CRI: Castelli’s risk index; CVR: Cardiovascular risk; IL: Interleukin; MCP: Monocyte chemoattractant protein; NAFLD: Nonalcoholic fatty liver disease; PAI: Plasminogen activator inhibitor; TIMP: Tissue inhibitor of metalloproteinase.